STOCKHOLM, Sept. 16, 2020 /PRNewswire/ -- SciBase Holding
AB ("SciBase") (STO:SCIB), a leading developer of augmented
intelligence-based solutions for skin disorders, announced today
that both the Journal of the American Academy of Dermatology (JAAD)
and SKIN, The Journal of Cutaneous Medicine (SKIN), have published
studies assessing the clinical impact of Nevisense. The
studies compared the results of US clinicians evaluating atypical
pigmented skin lesions (atypical moles) using visual evaluation
only compared to visual evaluation and the Nevisense result
combined.
The JAAD publication titled "Impact of Electrical Impedance
Spectroscopy on Dermatologists' Number-Needed-to-Biopsy Metric and
Biopsy Decisions for Pigmented Skin Lesions" sought to
evaluate improvements in clinical accuracy in melanoma detection,
while the SKIN publication titled "Integrating Electrical
Impedance Spectroscopy into Clinical Decisions for Pigmented Skin
Lesions Improves Diagnostic Accuracy: A Multitiered Study"
sought to evaluate the differences between practicing
dermatologists, physician's assistants, nurses and residents. All
clinician types (dermatologists, physician's assistants, nurses and
residents) improved by similar amounts, and the clinicians with the
lowest number of correct evaluations improved the most. The
publications are based on clinical evaluations of lesions in reader
studies. The JAAD publication included 267 dermatologists while the
SKIN publication included 591 clinicians (dermatologists,
physician's assistants, nurses and residents). All clinicians
evaluated lesions using visual evaluation only, and then they added
the Nevisense information in over 25,000 evaluations.The key study
takeaways
were:
- The number of `missed melanomas' fell from ~7% to <
1%
- Overall sensitivity (ability to correctly identify melanoma)
increased on average across the groups by 14% and specificity
(ability to accurately identify benign moles) by
10.2%
- In total, clinicians identified 1,343 more melanomas with
Nevisense compared to visual evaluation
alone.
- All clinician types (dermatologists, nurses and residents)
improved a similar amount, and the clinicians with the lowest
number of correct evaluations improved the
most.
- In the JAAD study, dermatologists improved their sensitivity
from 84 to 98%, their specificity from 34% to 44% and their NNB
(Number Needed to Biopsy) from 6.3 to 5.3.
"Melanoma is the deadliest form of skin cancer, but when
detected early, treatment has a nearly 100% cure rate making early
detection critical to survival. These studies show a significant
reduction of missed melanomas from ~7% to less than 1%, a further
indication of the clinical value Nevisense can bring by helping
clinicians identify melanomas and improve performance across the
board. This is the first time this type of study has been performed
and we are pleased with the results," stated Dr. Darrell S. Rigel, Clinical
Professor, Ronald O. Perelman Department of Dermatology at NYU
Grossman School of Medicine. "These results further demonstrate
the benefits of early melanoma detection with Nevisense, and I am
pleased that we are able to share our findings with the clinical
community demonstrating the benefits of this technology for
patients."
"Clinicians face difficult decisions every day when they
evaluate moles, so it was very positive to see that Nevisense could
so significantly improve their accuracy. Nevisense was able to help
clinicians of all levels of experience, and especially those who
were most in need of support," said Simon Grant, CEO of SciBase. "Dr.
Rigel's studies confirmed what we see from our users in the field -
significant clinical benefit for both clinicians and patients. This
is further proof of the potential for Nevisense to improve the
standard of care of melanoma detection in the United States and will provide timely
support to our ongoing reimbursement process."
For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com
Certified Advisor (CA):
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company,
headquartered in Stockholm that
has developed and sells a unique point-of-care device for
evaluation of skin disorders such as skin cancer and atopic
dermatitis. Its first product, Nevisense, helps doctors to detect
malignant melanoma, the most dangerous type of skin cancer. Further
development has led to Nevisense also being used as a tool to
assess the skin barrier and inflammation. SciBase was founded by
Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on
substantial research and has achieved excellent results in the
largest clinical study ever conducted on the detection of malignant
melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in
the United States. Nevisense is
based on a method called Electrical Impedance Spectroscopy (EIS),
which uses the varying electrical properties of human tissue to
categorize cellular structures and thereby detect malignancies and
abnormalities. SciBase is listed on First North Growth Market
("SCIB"). Further information is available
at www.scibase.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/scibase/r/new-clinical-studies-show-improved-melanoma-detection-by-us-clinicians-with-nevisense,c3194683
The following files are available for download:
https://mb.cision.com/Main/12371/3194683/1306674.pdf
|
Release
|